Latest News

"A 30% discrepancy in results." During his talk at EACVI, Professor James Moon shared the moment he realised the tools doctors relied on simply weren't good enough. For a clinician dealing with heart failure, that ambiguity was unacceptable. This is the story of how a concern for "metrology", the science of measurement, turned into a mission to exceed human performance. From scanning patients o....

We are delighted to announce a major strategic partnership between MyCardium AI and Optum | Change Healthcare Enterprise Imaging Healthcare, one of the largest and most trusted enterprise imaging and PACS integration providers in the world. This collaboration represents a significant milestone for MyCardium AI and marks the beginning of a new era in cardiovascular imaging, where intelligent a....

MyCardium AI has been recognised among the UK’s top 16 AI startups to watch, following its inclusion in Sifted’s latest feature highlighting ventures shaping the future of artificial intelligence across multiple industries. The article, based on insights from leading venture capital firms including Amadeus Capital Partners, Baltic Ventures, Ada Ventures and others, identifies emerging....

London, UK - October 2025 MyCardium AI is proud to announce its role as the Core Laboratory in the recently published NEJM study: Immediate or Deferred Nonculprit-Lesion PCI in Myocardial Infarction. The trial investigated whether percutaneous coronary intervention (PCI) of nonculprit lesions should be performed immediately or deferred in patients with myocardial infarction. This study has signi....

MyCardium AI has been featured in the Financial Times article, “AI start-ups make big gains in healthcare.” The feature highlights a new generation of innovators using artificial intelligence to accelerate clinical decision-making and improve patient outcomes across global healthcare systems. As a spin-out from University College London (UCL), one of the world’s leading centres ....

EchoConfidence Receives FDA 510(k) Clearance We’re thrilled to share a major milestone at MyCardium AI, our AI-powered echocardiography platform, EchoConfidence, has officially received FDA 510(k) clearance! This clearance not only confirms the safety and effectiveness of EchoConfidence, but it also paves the way for the platform’s clinical use in the United States, bringing explai....

We were proud to sponsor this year’s British Cardiovascular Society (BCS) Annual Conference, where clinical education and cutting-edge technology came together to shape the future of cardiac imaging. As part of our commitment to advancing cardiovascular care, we showcased 1CMR Pro, our AI-powered cardiac MRI analysis solution, through an expertly delivered hands-on educational program. A Te....

Liverpool, UK – MyCardium AI, a pioneering Healthtech company developing cutting edge AI solutions for cardiac imaging, is proud to announce that it is now an official member of AXREM, the UK trade association representing the medical imaging and radiotherapy industry. By joining AXREM, MyCardium AI reinforces its commitment to collaboration, standards, and innovation within the UK ....

We are proud to announce that EchoConfidence has officially received CE Class IIb certification. A major milestone that reflects our unwavering commitment to safety, quality, and innovation in healthcare technology. What does Class IIb mean? This classification is reserved for medium-to-high-risk medical devices and indicates rigorous regulatory scrutiny. CE Class IIb approval confirms that 1E....

We’re thrilled to announce that our cutting-edge 1CMR Pro AI software has officially received CE Class IIb approval! This certification is a significant milestone, reinforcing our commitment to providing innovative, regulatory-approved AI solutions that enhance cardiovascular diagnostics. With CE Class IIb approval, MyCardium AI can now bring 1CMR Pro to more clinicians across Europe, help....